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EDITORIAL    
The End of the Digoxin Era?  
Antonis S. Manolis, MD, Helen Melita, MD  
Athens University School of Medicine and Onassis 
Cardiac Surgery Center, Athens, Greece  
ABSTRACT 
Digoxin is one of the oldest of cardiovascular drugs 
which is still frequently used, both in patients with atrial 
fibrillation (AF) and patients with heart failure with or 
without AF. The use of digoxin preceded the era of 
evidence based medicine. However, over the recent past, 
there has been growing evidence disputing and challenging 
the safety and efficacy of digoxin, while evidence has 
accumulated that a plethora of other therapies for both 
heart failure and atrial tachyarrhythmias has proven more 
effective and safe. Nevertheless, digoxin still retains its 
role, albeit limited, in the current era, but most recent 
evidence has cast significant doubts about its safety. Thus, 
its role remains controversial and the drug should be 
reserved for specific patients and clinical scenarios, with 
careful monitoring of its serum concentration due to its 
narrow therapeutic and toxic ranges, maintaining it <0.8 
ng/mL, with additional monitoring of serum electrolytes 
and renal function to avoid potential confounders that may 
enhance the proarrhythmic risk and susceptibility to 
digoxin toxicity.   
Key Words: digitalis; digoxin; atrial fibrillation; heart failure; 
mortality; proarrhythmia; digoxin toxicity  
Abbreviations 
AF = atrial fibrillation; CRT-D = cardiac resynchronization 
therapy-defibrillator; DIG = Digitalis Investigation Group; HR 
= hazard ratio; ICD = implantable cardioverter defibrillator; 
NYHA = New York Heart Association; TTR = time in 
therapeutic range; VF = ventricular fibrillation; VT = ventricular 
tachycardia  
INTRODUCTION  
Digoxin has been included in our therapeutic 
armamentarium for heart failure and atrial 
tachyarrhythmias for over 200 years following Withering's 
milestone work suggesting the therapeutic value of the 
plant foxglove in his 1785 classic monograph.1 However, 
there has never been any evidence of a survival benefit,2 
while recently, evidence has accumulated suggestive of a 
harmful effect.3-6 While in atrial fibrillation (AF) digoxin 
may have a role in the control of ventricular rate when 
added to beta-blockers and calcium antagonists, which 
may have to be revisited in light of this recent evidence, 
digoxin for heart failure may no longer be a supportable 
option in view of all the data that have been accumulated 
todate.  
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Since the results of the Digitalis Investigation Group 
(DIG) trial,2 indicating that digoxin does not reduce overall 
mortality, but it may reduce the rate of hospitalization both 
overall and for worsening heart failure, over long-term 
follow-up (3 years),2 but also during the first 30 days,7 the 
role of digoxin was further limited in the management of 
chronic heart failure, especially when more beneficial 
therapies for patients with heart failure were effected. 
Digoxin has also been employed in patients with AF to 
control the ventricular rate by enhancing vagal tone and 
thus decreasing conduction over the atrioventricular node. 
However, these effects are relevant only at rest and not 
during physical activity, since digoxin has limited utility in 
the setting of increased sympathetic activity. Thus, for 
more effective rate control the drug should be used in 
combination with a beta-blocker or a calcium antagonist. 
Furthermore, digoxin’s beneficial effects are offset by its 
potential deleterious effects, arrhythmogenic potential, 
narrow therapeutic window and risk for serious drug 
interactions. 
Indeed, recent meta-analyses and reviews of non-
randomized studies have suggested that digoxin use is 
associated with an increased risk of all-cause mortality in 
patients who have both heart failure and AF, even after 
adjustment for confounding variables.   
Atrial Fibrillation  
According with a US retrospective study (TREAT-AF: 
The Retrospective Evaluation and Assessment of 
Therapies in AF),6 among 122,465 male patients (mean 
age 72 years) with newly diagnosed nonvalvular AF with 
353,168 person-years of follow-up, cumulative mortality 
rates were higher for 28,679 (23.4%) digoxin-treated 
patients than for untreated patients (95 vs 67 per 1,000 
person-years; p < 0.001). Digoxin use was independently 
associated with mortality after multivariate adjustment 
(hazard ratio -HR: 1.26, p < 0.001) and propensity 
matching (HR: 1.21, p < 0.001), even after adjustment for 
drug adherence. The authors concluded that digoxin was 
associated with increased risk of death in patients with 
newly diagnosed AF, independent of drug adherence, 
kidney function, cardiovascular comorbidities, and 
concomitant therapies.  
Another US retrospective cohort study, the 
AnTicoagulation and Risk factors In Atrial fibrillation-
Cardiovascular Research Network (ATRIA-CVRN) 
study,8 comprising 14,787 age- and gender-matched adults 
with incident AF and no previous heart failure or digoxin 
use, indicated that during a median 1.17 years of follow-
up, digoxin use was associated with higher rates of death 
(8.3 vs 4.9 per 100 person-years; P<0.001) and 
hospitalization (60.1 vs 37.2 per 100 person-years; 
P<0.001); digoxin use conferred a 71% higher risk of death 
(hazard ratio, 1.71) and a 63% higher risk of 
hospitalization (hazard ratio, 1.63). The authors concluded 
that in adults with AF, digoxin use was independently 
associated with higher risks of death and hospitalization 
and thus it should be used with caution in the management 
of AF.  
A recent study investigated whether AF patients 
receiving rate control drugs (N = 101,243) had a better 
prognosis compared to those without rate-control 
treatment (N = 168,678).9 Rate controlled agents included 
beta-blockers (n = 43,879), calcium channel blockers (n = 
18,466) and digoxin (n = 38,898). During a follow-up of 
4.9±3.7 years, mortality occurred in 88,263 patients 
(32.7%). The risk of mortality was lower in patients 
receiving beta-blockers (hazard ratio - HR = 0.76) and 
calcium channel blockers (HR = 0.93) compared to those 
who did not receive rate-control agents. On the contrary, 
the digoxin group had a higher risk of mortality with a HR 
of 1.12. The authors concluded that in this nationwide AF 
cohort, rate-control treatments with beta-blockers or 
calcium channel blockers reduced mortality, with beta-
blockers conferring the largest risk reduction, while 
digoxin use was associated with greater mortality.  
 Even in a “real world” cohort of 815 AF patients on 
good anticoagulation treatment (time in therapeutic range 
- TTR ~65%), the use of digoxin (n=171) was associated 
with an increased risk of total mortality over a median 
follow-up of 33.2 months.10 Indeed, multivariable analysis 
showed that digoxin was associated with total mortality 
(hazard ratio -HR: 2.224, p < 0.001) and cardiovascular 
death (HR: 4.686, p < 0.001).   
Heart Failure  
 The Digitalis Investigation Group (DIG) trial was the 
pivotal trial showing that digoxin reduces the risk for 
hospitalization but not mortality among 6,800 stable 
patients (mean age 65 years) with heart failure (NYHA 
functional class II or III) and a left ventricular ejection 
fraction <45% who were in sinus rhythm.2 The DIG 
ancillary trial had a similar design and was conducted in 
parallel to the main study but included patients with 
ejection fractions >45% (“diastolic” heart failure or heart 
failure with preserved ejection fraction).11 The ancillary 
trial comprised 988 patients and found no effects on all-
cause, cardiovascular, or heart failure mortality or on all-
cause or cardiovascular hospitalizations.  
Post-hoc analyses of the DIG trial and other trial 
databases prompted the revised recommendation 
suggesting a much lower (0.5 to 0.8 ng/ml) than previously 
considered therapeutic serum digoxin level (1.0 to 2.0 
ng/ml) in order to obtain the favorable effects of digoxin 
and avoid its deleterious consequences on long-term 
survival.12 Unfortunately, despite these recommendations 
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for lower dosing and the accumulation of worrisome data 
about the long-term use of digoxin, digoxin toxicity is not 
yet declining according with the US data, accounting for 
an estimated 1% of emergency room visits for all adverse 
drug events among patients ≥40 years, rising to ~3% of 
emergency room visits and ~6% of hospitalizations for all 
adverse drug events among patients ≥85 years.13  
Recently, in the cohort of 1820 patients with mild heart 
failure (NYHA class I and II), prolonged QRS duration (> 
130 ms), and reduced left ventricular ejection fraction 
(<30%) enrolled in the Multicenter Automatic 
Defibrillator Implantation Trial – Cardiac 
Resynchronization Therapy (MADIT-CRT) trial,14 
digoxin therapy was not associated with an increased or 
decreased risk of heart failure/death (hazard ratio -HR 
1.07), heart failure alone (HR 1.1), or death alone (HR 
0.93). However, digoxin was associated with a significant 
41% increased risk of ventricular tachycardia / ventricular 
fibrillation (VT/VF) (HR 1.41; P = 0.002), which was 
driven by a significantly increased risk of VT/VF with 
heart rate >200 bpm (HR 1.65; P < 0.001), whereas no 
increased risk of VT/VF with heart rate <200 bpm was 
evident (HR 1.20; P = 0.19). The authors concluded that 
the use of digoxin in patients with mild heart failure 
implanted with an implantable cardioverter defibrillator 
(ICD) or cardiac resynchronization therapy-defibrillator 
(CRT-D) device was not associated with reductions in 
heart failure/death events; however, digoxin therapy was 
associated with an increased risk of high-rate VT/VF.  
Atrial Fibrillation and Heart Failure  
A meta-analysis of 10 studies ( 4 registries, 4 single-
center cohort studies and 2 post-hoc analyses of 
randomized controlled trials) comprising 76,100 patients 
with AF and heart failure indicated that over a follow-up 
period of 0.8-4.3 years, digoxin was associated with an 
increased risk of all-cause mortality (relative risk - RR: 
1.15, p=0.005).3 Subgroup analysis revealed that the 
pooled relative risk of all-cause mortality with the use of 
digoxin was similar between 8 observational studies (n = 
66,174, RR: 1.11) and 2 post-hoc analyses of randomized 
controlled trials (n = 9926, RR: 1.27, interaction p=0.11). 
The authors concluded that digoxin use is associated with 
an increased risk of all-cause mortality in patients who 
have both heart failure and AF, even after adjustment for 
confounding variables.  
A meta-analysis of 11 observational studies, examining 
the relation between digoxin and all-cause mortality in 
318,191 patients with AF, indicated that over a mean of 2.8 
years, digoxin use was associated with a 21% increased 
risk for mortality (hazard ratio 1.21).15 Importantly, the use 
of digoxin was associated with an increase in mortality in 
patients with and those without heart failure.  
Use and outcomes of digoxin were examined in the 
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET AF) trial.16 Among 14,171 AF patients (history 
of heart failure 56%-73%; digoxin use at baseline 37%), 
digoxin was associated with increased all-cause mortality 
(5.41 vs 4.30 events per 100 patients-years; hazard ratio-
HR 1·17; p=0.0093), vascular death (3.55 vs 2.69 per 100 
patient-years; HR 1·19; p=0.0201), and sudden death (1.68 
vs 1.12 events per 100 patient-years; HR 1·36; p=0·0076). 
The authors concluded that digoxin treatment was 
associated with a significant increase in all-cause 
mortality, vascular death, and sudden death in patients with 
AF, noting that this increased cardiovascular hazard was 
observed in those with and without heart failure. The 
authors also indicate that other drugs, such as β blockers 
and non-dihydropyridine calcium channel antagonists, 
should be employed for rate control in patients with AF, 
whilst digoxin treatment should not be deemed a first-line 
treatment and should be used with caution in patients with 
AF with or without heart failure. They point out that 
further randomized studies are needed to define the 
optimum rate control therapies, including the role of 
digoxin. 
 Another meta-analysis of 19 reports (9 comprising AF 
patients, 7 heart failure patients, and 3 with both clinical 
conditions) indicated that among 326,426 patients, digoxin 
use was associated with an increased relative risk of all-
cause mortality (hazard ratio - HR 1.21, P < 0.01).5 In the 
subgroup of reports comprising 235,047 AF patients, 
digoxin was associated with a 29% increased mortality risk 
(HR 1.29) compared with subjects not receiving the drug. 
Among 91,379 heart failure patients, digoxin-associated 
mortality risk increased by 14% (HR 1.14). The authors 
concluded that digoxin use is associated with an increased 
mortality risk, particularly among patients suffering from 
AF.  
The results of a more recent meta-analysis contrasted 
those of observational studies. This meta-analysis 
comprised 52 studies and 621,845 patients, whereby 
digoxin users were 2.4 years older than control, with lower 
ejection fraction (33% vs 42%), more diabetes, and greater 
use of diuretics and anti-arrhythmic drugs.17 Compared 
with control, the pooled risk ratio for death with digoxin 
was 1.76 in unadjusted analyses, 1.61 in adjusted analyses, 
1.18 in propensity matched studies, and 0.99 in 
randomized controlled trials. Baseline differences between 
treatment groups appeared to have a significant impact on 
mortality associated with digoxin, including markers of 
heart failure severity such as use of diuretics (P=0.004). 
Studies with better methods and lower probability of bias 
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were more likely to report a neutral association of digoxin 
with mortality (P<0.001). Across all study types, digoxin 
led to a small but significant reduction in all cause hospital 
admission (risk ratio 0.92; P<0.001; n=29,525). The 
authors concluded that digoxin is associated with a neutral 
effect on mortality in randomised trials and a lower rate of 
admissions to hospital across all study types (there were 7 
randomized trials included in the analysis conducted in 
8,406 heart failure patients).  
 Furthermore, a recent analysis of data from the ORBIT-
AF (Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation) study, among 9,619 patients with AF 
and serial follow-up every 6 months for up to 3 years, 
refuted the dismal results of prior reviews and meta-
analyses, albeit only for patients with heart failure.18 In this 
cohort, 2,267 (23.6%) patients received digoxin at study 
enrollment, 681 (7.1%) were started on digoxin during 
follow-up, and 6,671 (69.4%) never received digoxin. 
Digoxin use at registry enrollment was not associated with 
subsequent onset of symptoms, hospitalization, or 
mortality (hazard ratio - HR for death: 1.04 in heart failure 
patients; HR: 1.22 in patients without heart failure). 
Incident digoxin use during follow-up was not associated 
with subsequent death in patients with heart failure (HR: 
1.05), but was associated with subsequent death in those 
without heart failure (HR: 1.99). The authors concluded 
that digoxin use in registry patients with AF had a neutral 
association with outcomes under most circumstances, but 
digoxin was associated with subsequent death in those 
without heart failure (HR: ~2.0). 
 Similarly, a recent survey of a prospective, 
multinational, observational registry of 1962 patients with 
AF, aged 56 ± 16 years, 36% having a digoxin prescription, 
and 27% having heart failure, indicated that digoxin 
therapy was associated with significantly higher mortality 
in those without heart failure at 6 months (8.7% vs 3.7%; 
odds ratio - OR, 5.07; P <0.001) and 12 months (12.3% vs 
6.0%; OR, 4.22; P < 0.001) but not in those with heart 
failure (6 months: 18.6% vs 14.7%; OR, 1.62; P = NS and 
12 months: 25.4% vs 22.4%; OR, 1.37; P = NS).19 The 
authors concluded that in patients with AF and heart 
failure, digoxin did not offer any survival benefit, while in 
those without heart failure, digoxin therapy was associated 
with significantly higher long-term mortality.  
Conclusion and Perspective  
There appears to be convincing evidence accumulated 
todate suggesting that digoxin does not prolong survival in 
heart failure and/or AF patients, while there may be a 
significant risk of increased cardiovascular mortality in 
these patients. The data from recent reviews and meta-
analyses, admittedly mostly from observational studies, 
are worrisome and should be taken into serious 
consideration, especially in the current era, when we have 
much better and safer alternative therapies for both heart 
failure and AF. It may not possible to have in the future a 
randomized controlled trial that may be able to shed further 
light into this matter, while the results from other meta-
analyses refuting, albeit not entirely, the dismal outcome 
of digoxin use suggested by the majority of prior reviews 
and meta-analyses of observational data, do not appear to 
provide any convincing answers that would alleviate one’s 
fears for the potential perilous effects of digoxin.  
Thus, it is possible that we are indeed approaching the 
end of the digoxin era, saving it for now for only specific 
circumstances, such as patients with heart failure who are 
not responding well to standard therapies in hope of 
reducing their hospitalization rate, and patients with both 
heart failure and AF who cannot tolerate or do not respond 
to other available rate controlling agents. Even in such 
clinical conditions of last resort, one has to consider using 
the lowest possible dose of digoxin while maintaining its 
serum levels <0.8 ng/mL,20 with additional monitoring of 
serum electrolytes and renal function to avoid potential 
confounders that may enhance the proarrhythmic risk and 
susceptibility to digoxin toxicity (Fig. 1).   
  
Figure 1. A suggested algorithm for selective use of digoxin, 
if at all. With regards to digoxin toxicity, physicians should be 
alert and vigilant to discern between digoxin effect/ no toxicity 
(i.e., scooped ST-segment or ST-sagging), early toxicity (e.g. 
atrial or ventricular ectopy, bradyarrhythmia), moderate toxicity 
(i.e., ventricular arrhythmias, junctional rhythm), or severe life-
threatening toxicity (i.e., complete or high-degree AV block, 
ventricular tachyarrhythmias and hyperkalemia).12 AF = atrial 
fibrillation; CCB = calcium channel blocker; GFR = glomerular 
filtration rate; HF = heart failure; HFpEF = heart failure with preserved 
ejection fraction; HFrEF = heart failure with reduced ejection fraction; 
qd = once daily; qod = every other day; Rx = treatment.  
      Digoxin Use * 
 
 
 
HF patients      AF patients       AF/HF patients 
not responding     (no real need)     
to standard Rx                      combine with β‐blocker (HFrEF) 
                          combine with β‐blocker/CCB (HFpEF)
 
to ↓ hospitalizaƟon rate          to ↓ ventricular rate 
 
 
Dose: <0.125 mg qd/qod 
 
 
Serum digoxin level 0.5‐0.8 ng/mL  
(T ½ = 36 h when renal function is normal / steady state at 5 half‐lives) 
Monitor electrolyte & renal status 
 
 
Drug Interactions 
(e.g. amiodarone, dronedarone, propafenone, quinidine, verapamil, tetracycline, erythromycin) 
 
 
*  Avoid  or  extreme  caution  (much  lower  doses)  in  the  elderly  (>75‐80  years)  &  patients  with  renal
insufficiency  (GFR  <  45‐60  ml/min)  /  Digoxin  toxicity:  correct  hyperkalemia,  hypokalemia,  and
hypomagnesemia; correction of electrolyte imbalances may reverse dysrhythmias / Digoxin immune Fab is
extremely effective in the treatment of moderate to severe digoxin toxicity 
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